The implications that their FDA approved product Provenge and the rich pipeline of research is worthless is nonsense.
There must be pharmaceuticals with deep pockets that can find this company at 3,39 a steal.
Rhe risk return ratio in my opinion is very enticing
That's for almost 4,600,000 shares!!! Why? Who is buying?
I don't think it's Russian. Just because it's in cyrillic does not mean it's Russian. Although on the topic "Russian" I do hope that (Ras)Putin will get cancer of the prostate and be in need of Dendrean's product.
Rarely does one see options that are as richly priced as those in PSDA.
At present we have the following for PSDA
PSDA bid 4.46 and the asked 4.53
Jan 5 call bid 1 and the asked 1.25
Assume that you buy 1000 PSDA at asked $4530
ans sell 10 Jan 5 calls at bid $1000. Cost $3530 (of course you could do better)
If in January price of PSDA is unchanged the position will be worth $4530. 4530/3530=1.2833. That's a 111% annualized return.
If in January your stock is called your position will be worth $5000. 5000/3530=1.416 or 183% annualized return.
You coud lose money but only if PSDA is less than 3.53 in January, which of course is possible.
DNDN is priced as if there was no approval. I bought 4,000 shares today and will patiently wait for a much higher price. Been around long enough to see a bargain in a panic scene.
Agree with you that there is something afoot. I bought the may 40's in the morning for 5 and was able to unload them at 5.50 with the stock much lower. Very strange behavior.